Can a targeted drug combo beat the toughest childhood leukemia?
⭐️ CURE ⭐️
Recruiting now
This phase 2 trial tests whether adding dasatinib and blinatumomab to standard chemotherapy can improve outcomes for children aged 1 to 19 with very high-risk acute lymphoblastic leukemia. The study focuses on patients with specific genetic markers or who did not respond to initi…
Phase: PHASE2 • Sponsor: Hyoung Jin Kang • Aim: ⭐️ CURE ⭐️
Last updated Jul 31, 2026 00:00 UTC